Abstract-CD40 is a 48-kDa phosphorylated transmembrane glycoprotein belonging to the TNF receptor superfamily.
C D40 is a 48-kDa phosphorylated membrane glycoprotein belonging to the tumor necrosis factor (TNF) receptor superfamily. It was first described on human bladder carcinoma cells 1 but is also expressed on B lymphocytes, monocytes, dendritic cells, and endothelial cells. The ligand for CD40, CD40L or CD154, is a 39-kDa glycoprotein belonging to the TNF family. The importance of CD40L-CD40 interactions in the adaptive immune response was highlighted by the discovery that mutations in the CD40L gene are responsible for X-linked hyper IgM syndrome, a rare immunodeficiency disease characterized by the absence of both class-switched B cells and highaffinity antibody production. 2 Although the CD40L-CD40 interaction has been recognized to be of critical importance in the adaptive immune response for some time, it has now also been demonstrated to have an important role in inflammation. Ligation of CD40 on endothelial cells, [3] [4] [5] monocytes, 6 -8 and dendritic cells 9 results in activation with adhesion molecule and tissue factor expression and production of proinflammatory cytokines and chemokines. Recent work has demonstrated that CD40L-CD40 signaling is critical in the pathogenesis of atherosclerosis. 10 In addition to its role in inflammation and atherosclerosis, CD40L is involved in thrombosis: at high shear stress, CD40L binds directly to platelet ␣ IIb ␤ 3 via the integrin binding sequence KGD, enhancing thrombus formation and inducing platelet spreading via outside-in integrin signaling. 11 Platelets express membrane-bound CD40L on activation, which induces proinflammatory changes in endothelial cells via endothelial CD40. 12, 13 Platelets are the major source of soluble CD40L in the circulation, and the protean effects of CD40L have led some to suggest that platelet CD40L may be a pivotal link between the processes of thrombosis, inflammation, and atherosclerosis. 14 Clinical research has demonstrated that platelet CD40L expression is enhanced in acute coronary syndromes 15, 16 and that soluble CD40L is released after cardiopulmonary bypass. 17 Soluble CD40L is released from platelets following activation by thrombin, ADP, or collagen. 15 Henn et al 18 have demonstrated that this binds to CD40, also expressed on platelets, leading to further cleavage of membrane-bound CD40L and release of soluble CD40L. However, platelet activation by CD40L was not observed in this study. In the present study, we confirm that platelets constitutively express CD40 and demonstrate that platelet CD40 also provides a mechanism for platelet activation.
Materials and Methods

Patients and Subjects
The hospital research ethics committee approved the study protocol and informed consent was taken. Patients were 3 children with X-linked hyper IgM syndrome confirmed by mutational analysis and by absence of CD40L expression on activated T cells and platelets. One patient with Glanzmann's thrombasthenia with complete absence of ␣ IIb ␤ 3 expression was also investigated. All 4 patients were seen at Great Ormond Street Hospital for Children, United Kingdom. Controls were young adults working in the laboratory. No subject was taking any drug affecting platelet function at the time of the study.
Antibodies and Reagents
Recombinant hirudin was from Aventis. Adenosine diphosphate (ADP), arachidonic acid, aspirin, EGTA, probenecid, and chlorimipramine hydrochloride were from Sigma, UK. Collagen was from Organon Teknika and thrombin receptor agonist peptide 1 to 6 (SFLLRN) from BACHEM. Recombinant trimeric human CD40L (sCD40LT) was from Dr Richard Armitage (Amgen, Seattle, Wash 20 ; G1, an anti-CD62P antibody (Dr Rodger McEver, University of Oklahoma, Oklahoma City, Okla); and a nonspecific mouse IgG1 control (Becton Dickinson). Antibodies used in blocking experiments were azide free and used at saturating concentrations. sCD40LT was shown to be endotoxin-free using the limulus amoebocyte lysate endotoxin detection kit (Sigma). All concentrations given in subsequent sections are final concentrations in the reaction mixture.
Platelet Preparation and Activation
Blood samples were collected from healthy volunteers, discarding the initial 2 mL of blood taken in order to limit artifactual activation. Blood was transferred to polystyrene tubes containing either sodium citrate (0.38%) or hirudin (50 g/mL). Platelet-rich plasma (PRP) was prepared by centrifuging whole blood at 120g for 10 minutes. PRP or whole blood was stimulated with sCD40LT for 30 minutes at 37°C. In some experiments, samples were preincubated with 10 g/mL blocking antibodies or isotype-matched control antibody. SFLLRN (100 mol/L) as used as a positive control for platelet activation. To prepare washed platelets, PRP was spun at 800g for 5 minutes, and the pellet was washed with HBSS without cations and resuspended in RPMI-1640. Washed platelets were prepared in the presence of 30 ng/mL prostacyclin (Glaxo-SmithKline) to prevent platelet activation. Samples of purified platelets prepared in this way typically contained Ͻ0.01% leukocytes as assessed on a Bayer Technicon H3 blood analyser.
Culture and Activation of THP-1 Cell Line
The monocytoid cell line THP-1 was cultured in RPMI 1640 (Invitrogen) supplemented with 10% FCS, 2ϫ10 Ϫ5 M 2-mercaptoethanol (Sigma), 100 U/mL penicillin (Invitrogen), 0.1 mg/mL streptomycin (Invitrogen), and 2 mmol/L L-glutamine (Invitrogen) at 37°C in 5% CO 2 in air and maintained at 0.5ϫ10 6 cells/mL. The cells were stimulated for 72 hours with 100 IU/mL interferon-␥ (Boehringer-Ingelheim), which induces expression of CD40 mRNA and protein. 21 THP-1 cells were used as a positive control for the presence of CD40 mRNA and protein in the molecular biology and immunoblotting experiments.
Platelet Flow Cytometry
PRP or blood (5 L) was added to 50 L of platelet buffer 22 containing either FITC-conjugated or unconjugated CD40 monoclonal antibodies. The samples containing unconjugated antibody were washed, stained with FITC-goat anti-mouse Ig, and washed again. For the stimulation experiments, platelets were stained with Pac-1 FITC, CD40L PE, or CD62P PE antibodies. An isotype-matched IgG1 PE was used as a control. Experiments looking at Pac-1 binding were also performed in the presence of 2 g/mL eptifibatide (Schering-Plough), which we demonstrated in preliminary work completely blocks the ␣ IIb ␤ 3 ligand binding site, to determine nonspecific antibody binding. Fixative (250 L; 0.2% formaldehyde in phosphate buffered saline, pH 7.4) was added and the samples immediately analyzed on a FACSCalibur flow cytometer using Cellquest software (Becton Dickinson).
CD40 Immunoblotting and Detection of CD40 mRNA
Immunoblotting was performed as previously described 23 using the anti-CD40 antibody Mab89 as the primary antibody. cDNA was synthesized from RNA isolated from 10 9 platelets or 5ϫ10 7 interferon-␥-stimulated THP-1 cells. PCR of cDNA was performed, and the PCR products separated by electrophoresis on a 1% agarose gel and visualized with ethidium bromide. Amplification of human ␤-actin served as a control for sample loading and integrity. (For full methodology, see the expanded Materials and Methods section, which can be found in the online data supplement available at http://www.circresaha.org.)
Platelet-Dense Granule and ␣-Granule Release
Dense granule release was assessed by determining platelet [
14 C]-5-HT release as previously described (see online data supplement). 24 ␣-Granule release was assessed by determining platelet ␤-thromboglobulin release in the supernatant plasma from these experiments using a commercially available ELISA according to the manufacturer's instructions (Roche Diagnostics).
Assessment of Platelet-Neutrophil Complexes
Platelet-neutrophil complexes were assessed as previously described 25 (see online data supplement).
Electron Microscopy
PRP was fixed in 3% glutaraldehyde in sodium cacodylate buffer (0.1 mol/L sodium cacodylate, 2 mmol/L calcium chloride, pH 7.4) for 30 minutes and spun at 800g for 5 minutes to obtain a platelet pellet. The pellets were postfixed in osmium tetroxide, dehydrated in ethanol, and embedded in araldite resin before sectioning. Sections (70 nm) were cut, mounted on copper grids, and stained with uranyl acetate and lead citrate. Transmission electron microscopy was performed on a JEOL 1200EX electron microscope (JEOL).
Ca
2؉ Flux Measurements
Calcium flux was assessed as previously described 24 (see online data supplement).
Platelet Aggregometry
The residual blood after PRP collection was centrifuged at 1200g for 15 minutes at room temperature to obtain platelet-poor plasma (PPP). PRP with a final platelet count of 250ϫ10 9 /L was prepared by diluting PRP with PPP. Aggregometry was performed on a Biodata aggregometer at 37°C with a stir speed of 900 rpm. Light transmission was recorded after addition of known platelet agonists and of 1 g/mL sCD40LT. Costimulation experiments were performed with sCD40LT and 0.1 to 5 mol/L ADP or 0.1 to 1 mmol/L arachidonic acid to determine if sCD40LT had a synergistic effect with known platelet agonists.
Statistical Analysis
Each experiment was performed on platelets from the number of donors stated. The results are shown as meanϮSEM. Paired t tests were used for statistical comparisons.
Results
Human Platelets Constitutively Express CD40 Protein
Typical flow cytometry plots using unconjugated antibodies (G28.5 and Mab 89) are shown ( Figure 1A ) and show that CD40 is constitutively expressed on resting platelets. The presence of 48-kDa CD40 protein in platelets was confirmed by immunoblotting ( Figure 1B ). After stimulation with SFLLRN, there was a minor increase in CD40 expression, assessed using a directly conjugated antibody (14G7), from a median fluorescence intensity (MFI) of 10.9Ϯ0.3 to 15.8Ϯ0.6 (Pϭ0.003, nϭ5). SFLLRN stimulation also increased CD40L expression as previously described, 26 resulting in coexpression of CD40 and CD40L on 23.1Ϯ2.3% of platelets compared with 7.5Ϯ0.4% in unstimulated controls (Pϭ0.002, nϭ5).
Despite the presence of CD40 on the platelet surface, CD40 mRNA was not detected in platelets by reverse transcription PCR (Figure 2 ), suggesting that CD40 protein is preformed by megakaryocytes during platelet production.
CD62P Expression
Platelet activation with the agonists ADP, SFLLRN, or collagen results in expression of ␣-granule proteins, including CD62P. sCD40LT was similarly found to induce CD62P expression on platelets. A dose-response curve is shown ( Figure 3A) . Incubation of platelets with 1 g/mL sCD40LT increased the percentage of CD62P-positive cells from 15.2Ϯ0.9 to 46.7Ϯ2.8 (Pϭ0.0002, nϭ5). This was completely abrogated by the CD40L-blocking antibody TRAP-1 (Pϭ0.0002) and the CD40-blocking antibodies M2 (Pϭ0.0001) and M3 (Pϭ0.0001). There was no inhibition by isotype-matched control antibody ( Figure 3B ).
These results are consistent with platelet activation caused by ligation of CD40 by CD40L. However, CD40L has the integrin binding sequence KGD and Andre et al 11 have reported that sCD40L binds to platelets through interactions with ␣ IIb ␤ 3 . To investigate the possibility that sCD40LT-induced platelet activation is mediated by outside-in signaling through ␣ IIb ␤ 3 , sCD40LT-mediated platelet CD62P expression was investigated in the presence of the ␣ IIb ␤ 3 -blocking peptide eptifibatide. In these experiments, there was no reduction in the level of CD62P expression induced by sCD40LT ( Figure 3B ). Additionally, platelets from a patient with Glanzmann's thrombasthenia with complete absence of ␣ IIb ␤ 3 were normally responsive to sCD40LT (not shown).
␣-Granule and Dense Granule Release
sCD40LT caused both platelet dense granule and ␣-granule release in a CD40-dependent manner. sCD40LT increased ␤-thromboglobulin release from platelet ␣-granules from 2258Ϯ151 to 3692Ϯ211 IU/mL (Pϭ0.002, nϭ5) ( Figure  4A ). This response was inhibited by the CD40-blocking antibodies M2 (Pϭ0.002) and M3 (Pϭ0.01) and the CD40L blocking antibody TRAP-1 (Pϭ0.01) but not by isotypematched control antibody or by eptifibatide. Eptifibatide alone had no effect. sCD40LT increased [
14 C]-5-HT release from platelet-dense granules from 3.8Ϯ0.2% to 8.9Ϯ1.1% (Pϭ0.03, nϭ5) ( Figure 4B ). This response was inhibited by the CD40-blocking antibodies M2 (Pϭ0.04) and M3 (Pϭ0.04) and the CD40L blocking antibody TRAP-1 (Pϭ0.04) but not by isotype-matched control antibody or by the ␣ IIb ␤ 3 -blocking peptide eptifibatide. Eptifibatide alone had no effect.
Platelet-Leukocyte Complexes
In whole blood, CD62P expressed on platelets binds to neutrophils and monocytes, which express the specific counter-receptor, P-selectin glycoprotein ligand 1 (PSGL-1). 27 This adhesive interaction activates leukocytes and allows the formation of platelet-leukocyte complexes, 25 which are important in the recruitment of leukocytes to sites of thrombosis and tissue injury. 28 Because sCD40LT preferentially causes platelet CD62P expression rather than ␣ IIb ␤ 3 activation, we investigated the capacity of sCD40LT to cause the formation of platelet-neutrophil complexes in whole blood. Without platelet activation, 14.1Ϯ0.6% of neutrophils formed complexes with adherent platelets. This increased to 31.6Ϯ4.3% after stimulation with sCD40LT (Pϭ0.02, nϭ5). Platelet-neutrophil complex formation was inhibited by the CD40L blocking antibody TRAP-1 (Pϭ0.02), the CD40 blocking antibodies M2 (Pϭ0.03) and M3 (Pϭ0.03), and by the CD62P blocking antibody G1 (Pϭ0.01) but not by control antibody, showing that the effect requires a CD40L-CD40 interaction and that it depends on expression of platelet CD62P ( Figure 5 ). Similar results were obtained with platelet-monocyte complexes (not shown).
Platelet Shape Change
Platelet activation by sCD40LT also induced pseudopodia formation and other morphological changes typically associated with activation ( Figure 6 ).
CD40 Ligation Does Not Induce Intracellular Calcium Flux
sCD40LT did not induce intracellular calcium flux, in contrast to SFLLRN, which is known to cause calcium flux via activation of the G protein-coupled thrombin receptor PAR-1 ( Figure 7 ).
␤ 3 Integrin Activation
Platelet activation with the agonists ADP, SFLLRN, or collagen results in a conformational change in ␣ IIb ␤ 3 , causing it to expose its high-affinity ligand binding site, which is recognized by the monoclonal antibody Pac-1. 29 We found that sCD40LT caused a small but significant increase in Pac-1 antibody binding from an MFI of 19.9Ϯ1.8 to 28.1Ϯ2.9 (Pϭ0.004, nϭ5). This was inhibited by the CD40L blocking antibody TRAP-1 (Pϭ0.03) and the CD40 blocking antibodies M2 (Pϭ0.04) and M3 (Pϭ0.06). There was no inhibition by isotype-matched control antibody ( Figure 8A ).
To determine if sCD40LT can induce platelet aggregation, we exposed normal platelets to sCD40LT and measured aggregation in an aggregometer. Despite the modest increase in platelet surface Pac-1 binding indicating ␣ IIb ␤ 3 activation, sCD40LT did not induce aggregation of platelets ( Figure 8B ). sCD40LT did not alter the capacity of both ADP and arachidonic acid to induce platelet aggregation at a range of concentrations (not shown) and CD40L blocking antibody TRAP-1 had no effect on aggregation of platelets from normal controls (not shown). Moreover, platelets from patients with CD40L deficiency, which we have previously shown do not express CD40L on stimulation, 26 aggregated normally (Figure 8 ). These experiments demonstrate that CD40L is not involved in homotypic platelet adhesion via ␣ IIb ␤ 3 at the low shear rates encountered in an aggregometer.
Discussion
Platelets are important mediators of inflammation as well as hemostasis. They possess adhesion molecules, which facilitate interactions with neutrophils, monocytes, and endothelial cells, and can activate these cells through direct contact or through the release of soluble mediators. Platelets express the transmembrane signaling protein CD40L within seconds of activation, 12 and after platelet activation with thrombin, ADP, or collagen, a soluble form of CD40L is also released. Henn et al 18 have demonstrated that this binds to platelet CD40, leading to further cleavage of membrane-bound CD40L and release of soluble CD40L. However, platelet activation through CD40 has not been reported. In this present study, we show for the first time that platelets can be activated through ligation of constitutively expressed CD40.
Ligation of platelet CD40 by sCD40LT causes platelet CD62P expression, ␣-granule and dense granule release, morphological changes typically associated with activation, and modest increases in ␣ IIb ␤ 3 activation.
Platelets constitutively express CD40 and on stimulation with SFLLRN, 23.1% are induced to coexpress CD40L. Other cells also have the capacity to coexpress CD40L and CD40, including vascular endothelial cells and macrophages in vitro 30, 31 and in vivo in the context of atherosclerosis. 31 SFLLRN mimics the physiological action of thrombin; therefore, platelet CD40L-CD40 interactions should occur during thrombus formation-an everyday event in healthy individuals. Coexpression of CD40 and CD40L has been demonstrated in human thrombus, 18 and platelet activation with CD40L expression occurs even in the absence of thrombus formation in conditions such as sickle cell disease, 32 acute coronary syndromes, 16 and hypercholesterolemia. 33 Plateletderived CD40L may have the capacity to stimulate resting platelets by binding to CD40 during direct cell-cell contact or, as platelets are a major source of soluble CD40L, via release of soluble CD40L. Concentrations of sCD40L of up to 50 ng/mL have been reported in peripheral blood in humans in disease states. 34, 35 Although this is at the lower end of the range required for platelet activation in vitro (we found platelet activation occurred at concentrations of 100 ng/mL), much higher concentrations might be generated at sites of platelet activation and tissue injury.
The biological activity of platelet sCD40L is likely to depend not only on local concentration but also on whether it exists as a trimer or monomer. The soluble CD40L used in this investigation was a trimeric form held together by an isoleucine zipper motif, which is far more active than sCD40L monomer. 36 Whereas Henn et al 18 suggested that 18-kDa platelet sCD40L is monomeric, other workers have found that 18-kDa sCD40L sediments on a sucrose gradient with an apparent molecular mass of 56 kDa, 37 suggesting that it spontaneously forms trimers. Molecular modeling 38 and crystallography 39 suggest that membrane bound CD40L is also trimeric and therefore membrane bound CD40L is likely to have the capacity to cause platelet activation.
Andre at al 11 demonstrated that at high shear (1000/s) and during the formation of arterial thrombus in an animal model, CD40L can bind to the platelet ␣ IIb ␤ 3 ligand binding site via the KGD integrin binding sequence, and promote platelet spreading and thrombus formation. However, CD40L had no effect on aggregation at low shear. All our aggregometry experiments were also conducted at low shear (100/s), and the results indicate that CD40LT does not modulate platelet aggregation under these conditions. However, we did find that sCD40LT caused a modest increase in platelet ␣ IIb ␤ 3 activation. The increase in ␣ IIb ␤ 3 activation caused by sCD40LT was abrogated by both CD40 and CD40L blocking antibodies, indicating that activation was occurring as a result of a CD40L-CD40 interaction. This is an additional mechanism for CD40L-induced ␣ IIb ␤ 3 activation to that proposed by Andre et al and may also become important at high shear rates.
The principal effects of platelet CD40 ligation were therefore to induce platelet shape change and ␣-granule release. In contrast, ␣ IIb ␤ 3 activation was minimal. This pattern of activation is distinct from that seen with other platelet agonists. An explanation for this observation may be that ADP, thrombin, and thromboxane A 2 are G protein-coupled receptors, whereas CD40 is not. ␣ IIb ␤ 3 activation requires G protein-mediated inside-out signaling, which is always associated with intracellular calcium flux. 40 CD40 signals through protein kinase cascades, including protein kinase C (PKC). 41 PKC signaling also occurs in platelets but usually in combination with increases in cytosolic calcium. Interestingly, phorbol esters, which induce PKC signaling alone, have been reported to cause platelet secretion without raising cytosolic calcium levels and take several minutes to induce a weak aggregation response. 42, 43 The pattern of platelet activation caused by CD40, with substantive granule release but minimal ␣ IIb ␤ 3 activation could be consistent with platelet CD40 signaling via PKC. Our finding that sCD40LT does not induce calcium flux is also consistent with this explanation. However, further work is required to clarify the signaling pathways activated by CD40 ligation in the platelet.
The biological importance of platelet CD40-mediated platelet activation is likely to stem from the release of ␣ and dense granule release, the contents of which have a number of biological properties, including leukocyte activation. 44 The ␣-granule adhesion molecule CD62P is also of critical importance in the recruitment of leukocytes to sites of thrombosis and inflammation and in the formation of circulating platelet-leukocyte complexes. 25, 27 These complexes represent a subpopulation of neutrophils and platelets primed for adhesion, phagocytosis, and bacterial killing, 25 and their significance has been demonstrated in a number of clinical conditions including angina, multiple organ failure, and SIRS. The enhancement of platelet-leukocyte adhesion caused by ligation of platelet CD40 and the proinflammatory stimulus caused by the release of granule contents may be particularly important where platelets are in close proximity to cells expressing CD40L, such as platelets in thrombi, and T cells, macrophages, and endothelial cells in atherosclerotic plaques. 45 Induction of platelet-leukocyte adhesion through CD40-mediated platelet CD62P expression is likely to provide a mechanism whereby leukocytes can be directed to sites of thrombosis, inflammation, or tissue injury and in the initiation and propagation of atherosclerosis. Our findings suggest that CD40-mediated platelet activation is likely to provide a pivotal link between thrombosis and inflammation. 
